BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
81.99
-0.08 (-0.10%)
Aug 5, 2026, 4:00 PM EDT - Market closed

Revenue

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22
Net Product Revenue
506.23M362.37M2.88M
License and Services Revenue
53.05M128.32M218.85M
Royalty Revenue
20.68M11.39M169.00K
Revenue (Total)
579.96M502.08M221.90M

Key Performance Indicators

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22
U.S. - Geographic Revenue Distribution
72.20%6.00%
Europe, Middle East, and Africa (EMEA) - Geographic Revenue Distribution
25.30%59.50%
Asia-Pacific (APAC) - Geographic Revenue Distribution
2.50%34.50%